STUDresearch · Peptide

Cagrilintide

Also known as

Cagri · Cagrilintide acetate (research/compounded discussions) · Long-acting amylin analogue · Amylin receptor agonist (class framing) · DACRA (dual amylin and calcitonin receptor agonist framing) · AM833 / AM-833 (developmental / research designation) · NN9838 / NN 9838 (developmental designation) · NNC0174-0833 / NNC-0174-0833 (Novo compound code) · CagriSema component (fixed-dose combo with semaglutide)

Community talk. May be wrong. Not medical advice. Not a protocol. Not for human or animal use.

Open in the directory ↗

Peptide Lots of talk Systemic Subcutaneous Metabolic / GLP-1 class

Systemic — a long-acting amylin analogue studied for satiety and weight management; not a local tissue-repair peptide.

What people say Cagrilintide is a long-acting amylin analogue studied as a once-weekly subcutaneous obesity treatment, alone and with semaglutide. It is investigational, not an approved do-it-yourself product. Doses people talk about

Phase 2 monotherapy dose-finding0.3–4.5 mg SC once weekly

Randomized arms included 0.3, 0.6, 1.2, 2.4 and 4.5 mg; higher arms used staged escalation.

Phase 1b with semaglutide0.16–4.5 mg SC once weekly

Cagrilintide cohorts were combined with semaglutide escalated toward 2.4 mg over 16 weeks, then held four weeks.

Phase 3 CagriSema pairing0.25/0.25 to 2.4/2.4 mg weekly

A paired cagrilintide/semaglutide ladder is a different product-development context from cagrilintide monotherapy.

Community add-on reports~0.125–0.25 mg SC weekly in starting reports; wider self-use varies

Forum users describe low-dose add-ons and split schedules, often alongside high-dose incretins; product identity and tolerability are unverified.

These amounts are descriptive study or discussion contexts, not a recommendation or conversion between products.

Half-life & effect duration

Half-life in the body: Under-the-skin injectionAbout 159–195 hours — roughly 6.6–8.1 days
Felt duration people report: AppetiteNext-day suppression; some describe only a few quieter days before mid-week hunger returns
FatigueAbout 2 days in one account
Nausea / dry heavesAbout 4–5 days in some accounts
Other accountsShorter, different or absent effects

Timing context & sources

How it may feel Reports vary sharply: some describe next-day appetite suppression, nausea, diarrhea, burps, fatigue, sleepiness, restlessness or food aversion; others report little effect even after repeated use. Co-use with tirzepatide or other incretins is a major confound.

Cycles people discuss Trial windows include 26-week monotherapy, 20-week early combination and 68-week REDEFINE courses, with multi-week escalation. Community ongoing use or 8-weeks-on/8-off charts are different, unvalidated calendar choices. Timing Weekly trial dosing differs from forum same-day or mid-week add-on timing. People discuss protein intake and fatigue around injections; these habits do not establish a superior schedule. Stacks Semaglutide is the formal combination-study partner. Forum add-on use with tirzepatide or retatrutide adds attribution and tolerability uncertainty. Access talk RUO lyophilized vials: “Research use only / not for human consumption” is how 2026 forums describe getting it. That label is not QC. Labs people mention Glucose / A1c: Combo programs care about glycemic numbers in T2D; DIY stackers sometimes watch fasting glucose when layering amylin on an incretin. Watch for GI effects (core class): Nausea, vomiting, diarrhea, constipation, abdominal pain/discomfort — dose-related and worse during escalation.

Tap a line to jump into the full notes. Research only — may be wrong.

Timing context & sources

Half-life in the body

Phase 1b measured a cagrilintide half-life of 159–195 hours.

Median time to peak concentration was 24–72 hours across 0.16–4.5 mg cohorts given with semaglutide.

Small phase 1b combination study; not a subjective-effect duration, monotherapy guarantee or personal dosing interval.

Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant cagrilintide with semaglutide 2.4 mg (opens in a new tab)PubMed abstract lines 242–254: six weekly SC cagrilintide cohorts, four-week co-escalation intervals, PK endpoints, half-life 159–195 h and median Tmax 24–72 h.Single-centre phase 1b, 95 exposed participants, concomitant semaglutide and sponsor funding; exploratory PK is not subjective duration or an approved regimen.

Felt duration people report

Some accounts describe GI or fatigue effects lasting roughly two to five days, but many report shorter, different or absent effects.

Inspected posts include next-day appetite suppression, two-day fatigue, and four-to-five-day nausea or dry heaves; several involve tirzepatide or other confounds.

Anonymous accounts, uncertain identity and dose, co-use, selection bias and nonresponse prevent a dependable population clock.

First dose side effects (opens in a new tab)Next_Protection1065 described four to five days of nausea or dry heaves with tirzepatide and later reported self-reducing; other commenters reported little or no first-dose difficulty.Anonymous and unverified; doses, products and co-use vary, including tirzepatide. Self-reduction is an attributed action, not validated guidance; strong selection and reporting bias remain.
Taking cagrilintide alone (opens in a new tab)The original poster later clarified food intake and lurasidone use; another poster reported waking after sleep, while Short_Set_girly described months without benefit before giving up the combination.Anonymous, mixed monotherapy and add-on use, unverified products and uncontrolled co-medications; follow-ups do not establish consensus or a fixed offset.
Sleeeeepy (opens in a new tab)The original poster later reported no fatigue; another poster described stopping, while SureApartment9046 described two fatigued days followed by energy.Anonymous self-reports with uncertain products and doses; varied follow-ups do not establish consensus or a fixed symptom offset, and operational preparation discussion is not used as evidence.

Other context in this card

Once-weekly cagrilintide for weight management: phase 2 dose-finding trial (opens in a new tab)PubMed abstract: 57-site randomized phase 2 trial assigning once-weekly subcutaneous cagrilintide 0.3, 0.6, 1.2, 2.4, or 4.5 mg over 26 weeks, including up to six weeks of escalation.Sponsor-funded obesity dose-finding study; trial assignments and escalation are not an approved personal schedule.
Help — severe vomiting after a CagriSema blend dose (opens in a new tab)Original post and replies describing an unverified blend, decimal or syringe-unit ambiguity, repeated vomiting, and conflicting concentration or compatibility advice.Anonymous CagriSema-blend discussion rather than cagrilintide monotherapy; unverified identity and dose, conflicting calculations, and uncontrolled advice. No preparation arithmetic is reproduced.

What people say 25

Food noise: Community logs often report quieter cravings and easier portion stop; hard to isolate when stacked with sema/tirz/reta. forum
Weekly convenience: Once-weekly preferred over multi-daily short amylins (pramlintide mealtime injections). forum
vs single-agent incretins: Forums often compare mono cagri as weaker average weight tool than high-dose tirz or reta alone, but valued as the amylin ‘second axis’ add-on when incretin plateau or food noise returns. forum
2026 “whisper vs mute” talk: X/forum logs treat ~0.5 mg as a food-noise whisper and ~1 mg as a fuller mute on top of an incretin — n=1, not a trial arm. forumanecdote
Plateau-break stories: r/cagrilintide 2026 threads credit adding cagri to mid-dose tirz (e.g. ~8–10 mg) for stalled loss and quieter alcohol pull — confounded by deficit and the incretin already on board. forum
Alcohol quieting: Recurring 2025–26 logs say drink-thinking dropped after the add-on, same class story as other satiety shots. forumanecdote
Appetite / satiety: Earlier fullness and smaller meal size via amylin-pathway satiety — users and trials frame it as quieter ‘food pull,’ not stim energy. trial
Phase 2 mono (Lau et al. Lancet 2021, 26 wk, n=706): Once-weekly 0.3 / 0.6 / 1.2 / 2.4 / 4.5 mg → mean weight loss roughly ~6.0–10.8% vs ~3.0% pooled placebo (+ lifestyle counseling; ~500 kcal deficit guidance). trial
Phase 2 dose ladder (trial-product style means often cited): ~6.0–6.1% (0.3 mg), ~6.8% (0.6), ~8.4–9.1% (1.2), ~9.5–9.7% (2.4), ~10.6–10.8% (4.5) at 26 weeks — dose-related without clear plateau by week 26. Slight % differences across sources reflect estimand / rounding. trial
4.5 mg mono arm: Highest phase 2 dose beat liraglutide 3.0 mg daily on mean weight loss (~10.8% vs ~9.0%; ETD about −1.8%, p=0.03 in that program). trial
2.4 mg mono (phase 2): ~9–10% mean loss by ~26 weeks with diet/exercise counseling — the dose later locked into CagriSema arms. trial
Phase 1b + fixed sema 2.4 mg (Enebo et al. Lancet 2021, 20 wk): Cagri 0.16–4.5 mg coadministered with semaglutide 2.4 mg; cagri 1.2 and 2.4 mg added roughly ~6.0–7.4 percentage points of mean loss vs sema + placebo (e.g., ~15.7% / ~17.1% total at 1.2 / 2.4 vs ~9.8% pooled placebo-on-sema; 4.5 mg ~15.4% vs ~8.0% matched placebo). trial
REDEFINE 1 mono arms (68 wk): Cagrilintide 2.4 mg alone ~−11.5% (treatment-policy) / ~−11.8% (trial-product style); semaglutide 2.4 mg alone ~−14.9% / ~−16.1% — combo beat either alone (~+5.5 pp vs sema, ~+8.9 pp vs cagri alone). trial
REDEFINE 1 high thresholds: Greater shares hit ≥5%, ≥20%, ≥25%, and ≥30% loss vs placebo (all p<0.001 in reported coprimary/secondary analyses). trial
REDEFINE 1 cardiometabolic secondaries: Greater waist reduction (~−13.4 cm ETD vs placebo cited), systolic BP drop (~−6.7 mmHg ETD), and physical-function score gains in published coverage. trial
Glycemic (REDEFINE 2): ~73.5% of CagriSema participants reached HbA1c ≤6.5% vs ~15.9% placebo in reported figures — combo framed for weight + glucose in T2D. trial
Phase 2 T2D combo (Frias et al., 32 wk): CagriSema 2.4/2.4 ~−15.6% weight vs ~−8.1% cagri alone and ~−5.1% sema alone in that small program; HbA1c drop ~−2.2% combo vs ~−0.9% cagri mono and ~−1.8% sema mono (combo statistically superior to cagri mono on A1c, not clearly superior to sema alone). trial
REDEFINE 4 (open-label head-to-head, 84 wk): CagriSema 2.4/2.4 ~23.0% vs tirzepatide 15 mg ~25.5% (if-adhered estimand); treatment-regimen ~20.2% vs ~23.6% — primary noninferiority to tirzepatide not met; still large absolute loss and major forum comparison point. trial
GLP-1 combo logic: Amylin + GLP-1 cast as complementary satiety circuits (brainstem vs hypothalamic populations; dual gastric-emptying delay); additive mean loss in RCTs is not proof every DIY stack is additive. trial
vs pramlintide: Same hormone family, different product — weekly long-acting research/clinical path vs approved multi-daily mealtime diabetes adjunct; not dose-interchangeable. trial
Phase 2 mono vs liraglutide framing: 1.2 and 2.4 mg cagri were in a similar ballpark to liraglutide 3.0 mg daily; only 4.5 mg clearly superior in that 26-week dataset. trial
CagriSema REDEFINE 1 (no T2D, 68 wk, n=3417): Fixed 2.4 + 2.4 mg weekly — treatment-policy mean ~−20.4% vs ~−3.0% placebo; trial-product / if-adhered framing ~−22.7% vs ~−2.3% placebo. trial
REDEFINE 1 deep responders: On-treatment framing often cited ~40.4% of CagriSema participants ≥25% weight loss; supportive analyses also report ~50.7% reaching BMI <30 from mean baseline ~38 vs ~10.2% placebo. trial
REDEFINE 2 (T2D + overweight/obesity, 68 wk, n=1206): CagriSema 2.4/2.4 mean ~−13.7% vs ~−3.4% placebo (treatment-policy); ~−15.7% vs ~−3.1% if full-adherence framing. Responder cuts: ≥5% ~83.6% vs ~30.8%; ≥10% ~65.6% vs ~10.3%; ≥15% ~43.9% vs ~2.4%; ≥20% ~22.9% vs ~0.5%. trial
Meta-analysis framing (early RCTs pooled): CagriSema outperformed sema 2.4 alone on weight (~extra ~9 pp short-term pooled MD in one analysis); mono cagri ~comparable to sema/lira with significantly lower vomiting in that synthesis. trial

Doses people talk about 22

mcg translation: 0.16 mg = 160 mcg; 0.25 = 250 mcg; 0.3 = 300 mcg; 0.5 = 500 mcg; 0.6 = 600 mcg; 1.0 = 1000 mcg; 1.2 = 1200 mcg; 1.7 = 1700 mcg; 2.4 = 2400 mcg; 4.5 = 4500 mcg weekly. forum
Community mono charts (research-chem talk): Often mirror REDEFINE ladder 0.25 → 0.5 → 1.0 → 1.7 → 2.4 mg weekly SC; some vendor charts use coarser 0.6 → 1.2 → 1.8/2.4 → optional 4.5 mg mono steps. forum
Stay-low / lowest effective: Hold below 2.4 mg (or below 4.5 mg mono) when satiety is already strong or GI is rough — trial flexibility language and forums both discuss sub-max response. forum
DIY combo dose match (cagri + sema): Separate vials often aim for equal mg of cagri and sema (e.g., both 1.0 then both 1.7) to mimic 1:1 CagriSema; purity and actual fill are uncontrolled vs trial pens. forum
Cagri + tirz (same-week start talk): Minority charts start both low the same week (e.g., tirz 2.5 + cagri 0.25–0.3); higher early GI risk is the counter-argument in those threads. forum
Same-day vs split-day injects: Most stack threads dose both peptides the same calendar day at different SC sites; split-day is occasionally tried for GI attribution, not evidence-based superiority. forum
2026 micro-entry on a maxed incretin: r/cagrilintide replies to “I’m already on 15 mg tirz” cluster at 0.125–0.25 mg weekly, not a jump to 2.4 mg. 0.25 mg is repeatedly called a feeler that can still be “too much.” forum
Twice-weekly split (anecdote): Influencer/forum logs that felt 0.25 mg weekly wear off by day 3–4 split to 0.25 mg twice weekly (0.5 mg total) instead of doubling the weekly pin. forumanecdote
Contest / off-season charts (vendor blogs): Short hunger-control blocks at 0.5–1.2 mg vs longer 1.7–2.4 mg cuts — community templates, not REDEFINE. forum
Cagri + tirz (staggered community talk): Common research-forum pattern: run tirzepatide alone first ~8 weeks (e.g., 2.5 → 5 mg) to confirm GI tolerance, then add cagri at 0.25 mg and climb 0.25 → 0.5 → 1.0 → 1.7 → 2.4 every ~4 weeks while tirz titrates separately toward personal max (often ≤15 mg). Same-day different sites is the usual schedule talk — not an RCT protocol. forum
Cagri + reta (anecdotal only): Community references often stabilize reta first (~2 mg/week step, ~8–12 weeks in), then introduce cagri 0.25 mg and follow a separate 4-week ladder to 1.7–2.4 mg while reta holds or climbs slowly; theoretical five-pathway stack with zero completed combo RCTs. forum
Framing: Trial, protocol-chart, and community research ranges only — discussed for education, not advice or a use protocol. forum
Phase 1b combo cagri band (Enebo): 0.16, 0.30, 0.60, 1.2, 2.4, 4.5 mg weekly with semaglutide escalated toward 2.4 mg; one described path started 0.16 mg and stepped every ~4 weeks. trial
Common trial target (CagriSema era): 2.4 mg once weekly is the most-cited mono and combo component dose. trial
Maintenance after ramp: ~52 weeks at target in 68-week REDEFINE designs after the ~16-week escalation, then ~7-week off-treatment observation. trial
Hold / flexible steps (REDEFINE 1): Investigators delayed escalation or reduced dose for GI intolerance or low-BMI concern; ~57.4% still on max 2.4/2.4 at week 68; ~74.7% had received max dose at some point after randomization — sub-max doses still produced large mean loss. trial
Not pramlintide math: Mealtime pramlintide (Symlin) unit schedules are not interchangeable with weekly cagri mg charts. trial
Phase 2 mono band (Lau): 0.3, 0.6, 1.2, 2.4, and 4.5 mg once weekly SC (dose-finding; 0.3/0.6 arms fixed low dose, higher arms escalated). trial
Phase 2 mono escalation style (Lau higher arms): Faster climb — e.g., start ~0.6 mg, double about every 2 weeks toward 1.2 / 2.4 / 4.5 mg in that program — quicker than later phase 3 4-week steps. trial
High mono research ceiling: 4.5 mg weekly was the top phase 2 arm; extra mean loss over 2.4 mg was modest (~1 pp class difference in that dataset) — not a universal ‘must hit’ target, and combo programs capped cagri at 2.4 mg with sema. trial
CagriSema / REDEFINE titration (paired 1:1): Start ~0.25 mg of each drug → step every ~4 weeks (0.25 → 0.5 → 1.0 → 1.7 → 2.4 mg each) so full 2.4/2.4 is reached by ~week 16. trial
Frias phase 2 T2D titration (cagri path): 0.25 → 0.5 (wk 4) → 1.0 (wk 8) → then +0.7 mg every 4 weeks to 2.4 mg by week 16 — same endpoint, slightly different intermediate math than REDEFINE pen steps. trial

How it may feel 11

Days 1–7: Subtle satiety, mild nausea, or little change — long half-life means levels build; not a same-day stim kick. Some report early ‘full after a few bites’ even at micro starts. forum
Months 4–6+ / 68 wk: Hold dose; protein + resistance-training talk rises because large loss can include lean mass if intake collapses; hair thinning / alopecia appears more often with large multi-month deficits (class pattern, also flagged in REDEFINE AE tables). forum
Energy / under-fuel: Fatigue, dizziness, or ‘flat’ training when calories/protein crash under strong satiety — common stack-thread warning, also listed more frequently on active arms in REDEFINE. forum
Micro-start feel (2025–26): On high tirz/reta, 0.125 mg is a repeated “plenty / two tired days” first-pin story; 0.25 mg is the usual feeler; 0.5 mg first pins still produce night-of nausea/vomit in people who were fine on tirz alone. forumanecdote
Reta add-on lethargy: 2026 logs adding 0.25 mg cagri to ~10 mg reta call fatigue “no joke” and drop to 0.125 mg. forumanecdote
First-week fade: Some on 10 mg tirz + higher cagri say appetite quiet lasts a few days then returns mid-week — drives twice-weekly or mid-week stagger talk, not a PK table. forum
Weeks 1–4 (low start): GI adaptation window; REDEFINE-style starts at 0.25 mg each (combo) or low mono steps — scale often quiet while appetite may already blunt. Nausea often peaks early then settles on a stable low dose. trial
Weeks 5–16 (escalation): Step-ups roughly every 4 weeks toward 2.4 mg; nausea/vomiting/diarrhea often re-flare after each increase then settle on a hold; constipation can lag and persist longer than peak nausea. trial
Week ~17+ maintenance: Full 2.4 mg (mono or each drug in CagriSema) held; mean trial curves keep separating from placebo through months of maintenance. trial
Months 2–3: Phase 2 mono curves still falling through 26 weeks without plateau; many community logs say ‘full effect’ waits until past titration and multi-week accumulation. trial
GI time course: Worst during dose escalation; trials describe predominantly mild–moderate, often time-limited after a stable dose. Dual emptying delay (amylin + GLP-1 in combo) is the community explanation for rougher stacked GI. trial

Around the dose 7

Clock: Weekly trial dosing is distinct from forum timing. Stack threads describe same-day or mid-week placement to interpret nausea, but neither pattern proves superiority. forum
Food: Lifting threads describe strong satiety, very small meals, and concern about protein/calorie under-eating; shakes or yogurt are reported coping choices, not a validated dosing method. forum
Training: Some posters report fatigue or sleepiness during the first one or two days after a dose and describe missed training; that timing is anecdotal and highly variable. forum
Alcohol / event day: Shot-week drinking is a nausea story; some 2026 logs also say the desire to drink dropped. Forum habit, not a label. forum
Same-day vs split-day: Most stack threads pin both peptides the same calendar day at different sites. Split-day is for attribution, not proven superiority. forum
Unverified blend reports: Existing tirzepatide/retatrutide/cagrilintide blend discussion raises clouding, refrigerator instability, concentration, identity and compatibility concerns. Those reports do not establish a preparation method. forum
Difficult first-dose reports: Existing notes describe pausing or self-reducing from 0.25 to 0.125 mg, and vomiting reports after 0.5 mg alongside 10 mg tirzepatide. These are attributed actions and adverse experiences, not a validated adjustment rule or a substitute for medical care. forum

Cycles people discuss 9

Lowest effective maintenance: Some community and trial narratives hold sub-max dose long-term when weight trajectory and sides are acceptable (supported by REDEFINE flexibility outcomes). forum
No classic on/off peptide cycle: Unlike healing peptides, metabolic amylin use is usually continuous while weight goal or clinical program continues; occasional vendor ‘8 weeks on / 8 off’ charts exist but conflict with obesity-trial continuous-use logic. forum
Restart after gap: Forums warn to retitrate from a lower step rather than jumping back to prior high dose — GI intolerance risk. forum
Titration on-ramp: ~12–16+ weeks of step-ups before stable maintenance is the trial norm for 2.4 mg targets (REDEFINE/Frias); phase 2 mono high arms used faster ~2-week doubles. trial
Trial block length: REDEFINE 1/2 used ~68 weeks treatment (escalation + ~52-week maintenance) plus short off-treatment follow-up (~7 weeks in REDEFINE 1 description). trial
REDEFINE 4 window: Open-label head-to-head vs tirzepatide reported at ~84 weeks — longer public comparison horizon. trial
Phase 2 mono length: 26-week primary weight endpoint for dose-finding; phase 1b combo was 20 weeks; Frias T2D combo 32 weeks. trial
Long-term unknowns: Years-long mono safety and CV outcomes are less mature than for approved GLP-1 RAs; REDEFINE-3 MACE-style work is part of the combo program discussion. trial
Chronic / ongoing framing: Obesity programs treat multi-month continuous use as the model; regain after stop is a class theme, not a planned ‘blast.’ trial

Timing 8

Steady state: Multi-week accumulation; early weeks understate later exposure and side-effect risk after escalation. forum
After last dose: Residual effect can lag multiple half-lives (roughly ~2–4+ weeks of declining levels depending on prior steady-state dose). forum
Injection day timing: Weekly same-day schedule is the trial standard; time-of-day is less debated than for short-acting injectables. Missed-dose guidance in community talk is usually ‘inject when remembered if within a few days, then resume weekly’ — not formal labeling for research powder. forum
Half-life: Roughly ~159–195 hours (~6.6–8.1 days); geometric means near ~180–195 h reported in PK work — supports once-weekly dosing. trial
Tmax: Median about ~24–72 hours post-SC (often cited ~24–36 h range in summaries); not same-hour stimulant onset. trial
Phase 1b coadmin PK: Cagri exposure dose-proportional (AUC0–168h ~926 to ~24,271 nmol·h/L and Cmax ~6.14 to ~170 nmol/L across 0.16–4.5 mg in that study); did not meaningfully alter semaglutide exposure/clearance (sema t½ ~145–165 h, tmax ~12–24 h in same work). trial
Why weekly: Fatty-acid acylation / albumin binding extends exposure far beyond native amylin’s minutes-scale half-life. trial
QTc note: Dedicated thorough QT work escalating to 4.5 mg weekly reported no clinically relevant QTcF prolongation vs placebo (assay sensitivity confirmed with moxifloxacin). trial

Stacks 13

DIY cagri + sema (separate vials): Community mirrors 1:1 mg steps toward 2.4/2.4; dose match, purity, and sterility are uncontrolled vs trial pens. forum
Cagri + tirzepatide (‘cagri-tirz’): Gray-market premixes and forum stacks pair amylin with dual GIP/GLP-1; staggered start (tirz first, then cagri 0.25→2.4) is the most-repeated DIY schedule talk; no pivotal RCT defines a safe ratio — high GI and concentration-error risk. forum
Cagri + retatrutide: Theoretical five-pathway stack (amylin + GLP-1/GIP/glucagon); community often adds cagri only after reta is tolerated around ~2 mg; zero completed combo RCTs. forum
Vs switching instead of stacking: Many threads choose tirzepatide or retatrutide monotherapy rather than adding cagri to max-dose incretins when food noise is already low. forum
Protein + resistance training: Recomp threads push high protein and lifting to blunt lean-mass loss under strong appetite suppression. forum
Not stacked with pramlintide: Short-acting amylin + long-acting cagri is not a studied dual-amylin strategy in obesity programs. forum
Other amylin/incretin neighbors (not stacks): Amycretin (Novo oral/SC amylin+GLP-1 single molecule), petrelintide, eloralintide — discussed as class competitors, not co-admin partners. forum
2026 reta+cagri pre-blends: Vendors sell “four-receptor” 20/4-style vials (e.g. 5:1 reta:cagri). Pitch is more pathways than CagriSema; evidence is the least of the category. forum
Hunter-style reta:cagri ratio talk: Some 2026 influencer logs run roughly 2:1 to 4:1 reta:cagri (e.g. 2–3 mg reta with 0.25–0.5+ mg cagri) so training-day eating still happens; 1:1 is called too much suppression for lean phases. forumanecdote
Bridge-off talk: Minority use cagri to hold appetite when cycling off reta — anecdote, not a withdrawal protocol. forum
CagriSema (primary clinical stack): Fixed-dose cagrilintide 2.4 mg + semaglutide 2.4 mg once weekly after paired 1:1 titration — main RCT and forum reference stack. trial
REDEFINE 4 context for stack debates: Head-to-head showed tirzepatide 15 mg slightly ahead of CagriSema on mean % loss at 84 weeks — fuels ‘just max tirz’ vs ‘add amylin axis’ forum splits rather than proving DIY cagri-tirz. trial
Lifestyle co-intervention: All major trials pair drug with diet/exercise counseling (~500 kcal deficit style guidance in earlier programs). trial

Access talk 6

RUO lyophilized vials: “Research use only / not for human consumption” is how 2026 forums describe getting it. That label is not QC. forum
Premix SKUs: Separate-vial 1:1 cagri+sema mimic, cagri-tirz 5/5-style blends, and reta+cagri 20/4-style 5:1 blends are sold as convenience. Ratio lock + unknown fill are the risk. forum
Trial pen ≠ gray puck: REDEFINE used a dual-chamber clinical device. Forum reconstitution math is not that product. forum
Prescription vs gray: There is no legitimate retail prescription path outside a trial. Everything else is gray. forum
No approved mono product: Cagrilintide is investigational. CagriSema (cagri 2.4 + sema 2.4) had an NDA filed Dec 2025; it is not a 2026 retail pen. trial
Cannot lawfully be compounded: FDA GLP-1 compounding pages state cagrilintide is not a component of an approved drug and is not on the 503A/503B bulks or shortage lists — compounded “cagri” or “CagriSema” is the same bucket as gray RUO in those writeups. trial

Labs people mention 4

Glucose / A1c: Combo programs care about glycemic numbers in T2D; DIY stackers sometimes watch fasting glucose when layering amylin on an incretin. trialforum
Not a unique cagri panel: People copy the GLP-class screenshot (weight trend, resting HR, how much protein they actually ate) more than a special amylin lab. forum
Premix identity: Third-party assay talk exists because the name on the vial is the whole risk — including sema labeled as cagri and the reverse. forum
Gallbladder / rapid-loss flags: Same RUQ-pain watch as other large-loss agents if the scale is moving fast. trial

Storage notes 2

No mix instructions here: STUDresearch does not list reconstitution, diluent volumes, or syringe unit charts. People reconstitute many different ways and vial labels differ — that content creates more confusion than clarity. forum
Storage (general talk only): Unopened research products are usually kept cool, dry, and away from light per the seller label. Anything after first use is product-specific — follow the label, not a universal forum SOP. forum

Related 10

Watch for 22

Pancreatitis class talk: Rare class concern shared with GLP-1-containing combos; severe persistent upper abdominal pain is a stop-and-evaluate red flag in community safety lists. forum
Over-suppression: Too little protein/calories → fatigue, nutrient gaps, hair/skin complaints, lean-mass risk — especially in multi-agonist stacks. forum
Source quality: Mislabel, under/over-fill, counterfeit research ‘cagri,’ and unknown salt/impurity profiles on gray vials. forum
Premix concentration disasters: Documented DIY cases of misreading multi-drug vial strength (e.g., 10× cagri) when switching products. forum
Investigational status: Not a substitute for approved obesity or diabetes drugs; research labels ≠ clinical authorization for self-administration. forum
Drug interaction caution (practical): Delayed gastric emptying can affect oral drug absorption timing — class discussion shared with GLP-1 RAs; peri-operative retained-gastric-contents talk is rising for the whole satiety-inject class. forum
Dehydration / acute kidney stress: Persistent vomiting + poor fluid intake is a practical risk theme in multi-agonist threads. forum
Identity mix-ups: Independent labs have caught vials labeled semaglutide that assayed as cagrilintide — wrong-peptide, not a dose-math error. forum
2026 first-pin overshoot: Starting 0.5 mg on an already-high tirz/reta base is the current vomit/fatigue diary pattern. Micro-start talk exists because of those posts. forum
GI effects (core class): Nausea, vomiting, diarrhea, constipation, abdominal pain/discomfort — dose-related and worse during escalation. trial
Phase 2 mono GI rates (Lau): GI AEs ~41–63% across cagri arms vs ~32% placebo; nausea ~20–47% vs ~18% placebo; primarily mild–moderate. trial
Phase 2 mono injection-site: Administration-site reactions dose-dependent ~13–43% on cagri vs ~13% liraglutide and ~3% placebo — erythema and local reaction common; rotate sites. trial
CagriSema GI load (REDEFINE 1): GI AEs ~79.6% combo vs ~39.9% placebo; mostly transient mild–moderate; nausea/diarrhea/vomiting peaked during escalation then fell; constipation more persistent. trial
CagriSema AE constellation (REDEFINE 1): Fatigue, dizziness, alopecia, gallbladder-related disorders, and injection-site reactions also more frequent on combo than placebo in AE tables (injection-site ~12.2% combo vs ~3.0% placebo in one published table; mono cagri injection-site ~16.9% in same table). trial
Discontinuation / max-dose reality: GI-related dropouts higher than placebo but often mid-single-digit percentage points in phase 3 coverage; many participants never held full 2.4/2.4 at week 68 despite high completion via dose flexibility. trial
Hypoglycemia (T2D / combo context): Level 1 hypo signals appeared more often with cagri-containing arms than sema alone in phase 2 T2D data (e.g., ~6–7% vs 0% in one small program); still low absolute rates vs insulin regimens. trial
Gallbladder / rapid loss: Cholelithiasis and biliary events are a shared caution with large weight-loss agents; REDEFINE flagged more gallbladder-related disorders on active arms. trial
Heart rate / CV class talk: Cagri programs report limited HR rise vs some GLP-1s in selected PK/safety work; dedicated QT study did not show clinically relevant QTc prolongation at 4.5 mg; long-term MACE data for combo still maturing. trial
Allergic / hypersensitivity: Trial AE tables include allergic-reaction categories at low rates (~5% range overlapping placebo in REDEFINE 1 table); standard peptide caution. trial
Pregnancy / special populations: Obesity trial populations were adult non-pregnant; not characterized for pregnancy, pediatrics, or many comorbidities outside protocols. trial
Cannot-compound watch: 2026 FDA language groups cagrilintide with retatrutide as not compoundable. “Clinic CagriSema” ads are the same legal bucket as RUO in those writeups. trial
Mono vs GLP-1 vomiting (meta framing): Early pooled analyses found significantly less vomiting with cagri mono vs sema/lira comparators, while CagriSema raised GI burden vs sema alone — mono-amylin sometimes pitched as ‘gentler vomit profile,’ combo is not. trial

Updated: 2026-09-01

Evidence mix Mixed trial + community tags Full: every bullet (trial + community). Use Scan for a faster bro-science read.

↑ Back to top

Half-life & effect duration

Timing context & sources⌄

Half-life in the body

Felt duration people report

Other context in this card

What people say 25

Doses people talk about 22

How it may feel 11

Around the dose 7

Cycles people discuss 9

Timing 8

More on what it is 10

Stacks 13

Access talk 6

Labs people mention 4

Storage notes 2

Related 10

Watch for 22

Timing context & sources